A detailed history of Aaron Wealth Advisors LLC transactions in Avidity Biosciences, Inc. stock. As of the latest transaction made, Aaron Wealth Advisors LLC holds 8,102 shares of RNA stock, worth $234,309. This represents 0.03% of its overall portfolio holdings.

Number of Shares
8,102
Previous 7,598 6.63%
Holding current value
$234,309
Previous $348,000 32.47%
% of portfolio
0.03%
Previous 0.04%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Jan 15, 2025

BUY
$29.08 - $52.5 $14,656 - $26,460
504 Added 6.63%
8,102 $235,000
Q3 2024

Oct 17, 2024

BUY
$37.21 - $48.14 $282,721 - $365,767
7,598 New
7,598 $348,000
Q4 2023

Jan 26, 2024

BUY
$4.87 - $9.37 $4,032 - $7,758
828 Added 0.62%
134,242 $1.21 Million
Q3 2023

Oct 19, 2023

SELL
$6.3 - $11.35 $22,012 - $39,656
-3,494 Reduced 2.55%
133,414 $851,000
Q2 2023

Jul 26, 2023

SELL
$10.62 - $17.34 $16,057 - $26,218
-1,512 Reduced 1.09%
136,908 $1.52 Million
Q4 2022

Jan 24, 2023

SELL
$10.06 - $22.66 $777,939 - $1.75 Million
-77,330 Reduced 35.84%
138,420 $0
Q2 2022

Jul 22, 2022

SELL
$11.18 - $20.5 $42.1 Million - $77.3 Million
-3,769,152 Reduced 94.59%
215,750 $3.13 Million
Q1 2022

May 10, 2022

BUY
$14.2 - $23.78 $53.5 Million - $89.6 Million
3,769,152 Added 1747.0%
3,984,902 $216 Million
Q4 2021

Jan 21, 2022

SELL
$20.4 - $28.66 $282,438 - $396,797
-13,845 Reduced 6.03%
215,750 $5.13 Million
Q2 2021

Jul 29, 2021

SELL
$19.62 - $29.26 $3.54 Million - $5.28 Million
-180,586 Reduced 44.03%
229,595 $5.67 Million
Q1 2021

Apr 29, 2021

SELL
$20.28 - $28.15 $2.31 Million - $3.21 Million
-114,058 Reduced 21.76%
410,181 $8.95 Million
Q4 2020

Feb 04, 2021

BUY
$24.73 - $35.12 $13 Million - $18.4 Million
524,239 New
524,239 $13.4 Million

Others Institutions Holding RNA

About Avidity Biosciences, Inc.


  • Ticker RNA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 52,127,000
  • Market Cap $1.51B
  • Description
  • Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic...
More about RNA
Track This Portfolio

Track Aaron Wealth Advisors LLC Portfolio

Follow Aaron Wealth Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Aaron Wealth Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Aaron Wealth Advisors LLC with notifications on news.